Disney, Uber, Eli Lilly and Shopify Report Quarterly Results as Novo Nordisk Falls on Outlook
Four large U.S.-listed companies posted second-quarter results on August 5, one day after Novo Nordisk's report sent its shares lower, with investors reading the batch for signals on consumer spending, obesity-drug demand and e-commerce ahead of Friday's jobs report.
Five Companies, One Number That Actually Matters
Novo Nordisk raised its full-year forecast on August 4. Its shares fell more than 6% anyway[9][11]. That single fact sits at the center of everything that happened over the next 24 hours, as Eli Lilly, Disney, Uber and Shopify all filed second-quarter results of their own on August 5[2][7][13].
None of the four disputed each other's numbers. Lilly's revenue jumped 48% to $23.0 billion, and the company raised its own full-year guidance to $85.0 billion to $87.0 billion[2]. Uber moved $58.02 billion through its app in gross bookings, beating estimates, while keeping $14.19 billion of that as revenue, just short of what analysts wanted[3][4]. Disney brought in about $25.2 billion, a bit under the roughly $25.41 billion consensus, and its stock still rose more than 4% before the opening bell[6]. Every one of those numbers is fact. What they mean is where the disagreement starts.
Why Beating Your Own Growth Isn't Enough
Here's the mechanism behind Novo's stock drop, and it explains a lot of what happened this week. Wall Street doesn't grade a company against last year. It grades a company against a consensus estimate, the average forecast that analysts publish before the report comes out[9][11].
Novo grew sales 7%, to 78.49 billion Danish kroner, and improved its full-year outlook from a range of down 4% to down 12%, to a narrower down 6% to flat[9]. That sounds like good news. But investors had priced in something better, specifically stronger sales of Novo's new Wegovy pill, and the pill came in under what analysts expected[9][11]. So the stock fell on a beat-the-competitor, miss-the-forecast quarter.
Shopify shows the same trap from the other side. After beating estimates in the first quarter, its stock still fell 16%, because the beat wasn't as big as buyers had already paid for[15]. Going into its second-quarter report, analysts wanted revenue near $3.43 to $3.44 billion[13][14]. The lesson repeats all week: a good quarter and a good stock day are not the same event.
The Fine Print Behind Lilly's 48%
Lilly's headline growth rate hides a split worth unpacking, and it's the split both obesity-drug makers are fighting over right now. In November 2025, Lilly and Novo Nordisk each struck deals with the Trump administration to lower U.S. list prices on GLP-1 drugs. Under the "most-favored-nation" arrangement, the U.S. price gets tied to the lower prices those same drugs sell for in other wealthy countries[18][22].
Injectable GLP-1 drugs launched on the new TrumpRx platform at $350 a month, set to fall to $245 over two years. New oral versions started at $149 a month, for Medicare, Medicaid and TrumpRx buyers[18][22]. The administration's argument is that Americans have long paid multiples of what other countries pay for the same drug. The industry's counter-argument is that higher U.S. prices are what funds the research behind new drugs used worldwide, so capping U.S. prices risks slowing that pipeline down.
Lilly's own numbers show how that tension plays out inside one earnings report. Prices actually worked against the company this quarter. Growth came almost entirely from volume, meaning more prescriptions filled at a lower price each[2]. Lower price per prescription means Lilly has to sell a lot more of the drug just to stand still, let alone grow 48%. So far, it has managed both[2].
Two Drugmakers, Two Different Bets
Lilly and Novo are effectively running the same experiment with different starting positions, and it's worth seeing both cases on their own terms. Lilly's argument is that it's building a category, not riding a fad: two guidance raises this year, plus FDA approval of Foundayo, an obesity pill sold under the brand name for orforglipron, and a new filing to use it for type 2 diabetes[1][2]. A pill is cheaper to manufacture and ship than an injector pen, which is why Lilly treats it as the next phase of the business, not a footnote[1].
Novo's argument is that it's being judged against an unrealistic curve. It's trading price for reach with its own oral Wegovy, deliberately pricing low to win volume and insurance coverage rather than protect margin, according to its leadership[10]. The company also points to years of cardiovascular outcome data on its injectables, data insurers use to justify covering the drug, as evidence that a rough quarter isn't the same as losing the broader market.
The stakes of that fight are large. Lilly held roughly 60.1% of the U.S. obesity and diabetes drug market in the first quarter of 2026, against about 39.4% for Novo[20]. Options traders going into Lilly's report were pricing in a possible swing of roughly $65.9 billion in the company's market value on the result alone, a measure of how much money is riding on which side turns out to be right[1].
Betting Big Before the Payoff Arrives
Uber, Shopify and Disney are all making a related bet: spend heavily now, ask investors to trust that it pays off later. Uber authorized a $20 billion stock buyback while committing more than $10 billion to autonomous-vehicle partnerships with companies including Rivian, Zoox, Verne and Pony.ai[4][5]. Its case is that gross bookings, the total value of every ride and delivery flowing through the app before Uber takes its cut, grew faster than expected[3][4]. Revenue, what Uber actually keeps, came in a little light partly because of a UK accounting change that altered how sales get recorded without changing the underlying business[4].
Shopify's version of the same bet is spending on AI infrastructure while merchants using its platform cleared more than $100 billion in goods sold in the first quarter, with revenue up 34% to $3.17 billion[12][14]. Disney is absorbing rising sports broadcasting rights fees, betting that live games keep an audience that would otherwise skip or pirate them[8]. This was only the second quarterly report under Disney's new CEO, Josh D'Amaro, who'd been in the job less than five months[6]. None of these bets can be verified by a single quarter's numbers. That's rather the point of a bet.
What Friday's Jobs Report Could Undo
Underneath all four earnings reports sits a variable none of these companies control: interest rates. At the Federal Reserve's last policy meeting, three regional bank presidents dissented in favor of raising rates immediately, an unusually large hawkish split[16]. Higher rates make future company profits worth less in today's dollars, which hits fast-growing, spend-now companies hardest, exactly the kind of company several of this week's reporters are.
That mechanism may explain a divergence showing up in the broader market. The Russell 1000 Growth index, a basket of faster-growing U.S. companies, was up just 0.32% for the year. The Russell 1000 Value index, made up of cheaper, slower-growing names, was up 20.67%, a gap of more than 20 percentage points[16]. An investor holding classic growth stocks has made almost nothing in 2026. One holding value stocks has made about a fifth of their money.
The Bureau of Labor Statistics releases the July jobs report on Friday, August 7[16][17]. Coverage of this week's results split along familiar lines: CNBC led several stories with the stock reaction rather than the underlying business[6][9], Benzinga led with a $65.9 billion options-implied swing rather than anything Lilly actually did this quarter[1], and StockTwits' own headline named the contradiction outright, that Novo's stock fell despite raised guidance[9]. Whether Friday's labor data moves markets more than anything these four companies said this week is, for now, still an open question.
Summary
Five large companies reported quarterly results on August 4 and 5, 2026. Eli Lilly, Disney, Uber and Shopify all posted results on Wednesday, August 5. Novo Nordisk reported a day earlier[9][13][7].
Eli Lilly said revenue rose 48% from a year earlier to $23.0 billion, and it raised its full-year revenue forecast to a range of $85.0 billion to $87.0 billion[2]. Novo Nordisk, its main rival in obesity and diabetes drugs, said sales rose 7% to 78.49 billion Danish kroner and improved its full-year outlook — yet its shares fell more than 6%, because sales of its new Wegovy pill came in under what analysts expected[9][11]. Uber reported gross bookings of $58.02 billion, above estimates, while revenue of $14.19 billion came in just under estimates[3][4]. Disney reported revenue of about $25.2 billion against a consensus estimate near $25.41 billion, and its shares rose more than 4% before the open[6].
The main genuine dispute is not about the numbers. All sides agree on what the companies filed. The dispute is about what the numbers mean. One reading says these results show a durable American consumer and a drug market still expanding fast. Another reading says the gains are narrow — concentrated in a few obesity drugs and a few platforms — and that price cuts, currency moves and heavy spending on artificial intelligence and self-driving cars will squeeze profits later. A third question sits underneath both: whether Friday's July jobs report and the Federal Reserve's next move matter more to these stocks than anything the companies said[16][17].
A second, more political dispute runs through the drug results. In November 2025 the Trump administration announced agreements with both Lilly and Novo Nordisk to lower U.S. prices on obesity drugs: injectable GLP-1 drugs would launch on the TrumpRx platform at $350 a month, declining to $245 over two years, while new oral versions would start at $149 a month, for Medicare, Medicaid and TrumpRx buyers[18][22]. Whether those cuts help or hurt the companies is contested, and this quarter is among the first to show the effect.
The Event
On Wednesday, August 5, 2026, Eli Lilly, The Walt Disney Company, Uber Technologies and Shopify each released quarterly financial results, with Disney and Lilly reporting before U.S. markets opened[2][7][13]. Lilly reported second-quarter revenue of $23.0 billion, up 48% year over year, and raised its full-year revenue guidance to $85.0 billion to $87.0 billion[2]. Uber reported second-quarter gross bookings of $58.02 billion and revenue of $14.19 billion, and forecast current-quarter adjusted profit below analyst estimates[3][4]. Disney reported fiscal third-quarter revenue of about $25.2 billion and reiterated its full-year outlook; its shares rose more than 4% in premarket trading[6]. Novo Nordisk had reported its own second-quarter results the previous day, August 4, and its shares fell more than 6%[9][11].
Undisputed Facts
- Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, a 48% increase from a year earlier[2].
- Eli Lilly raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion, up from the $82.0 billion to $85.0 billion range it set in April[2].
- Uber reported second-quarter gross bookings of $58.02 billion, above the roughly $57.06 billion analysts expected, and revenue of $14.19 billion, slightly below the roughly $14.24 billion expected[3][4].
- Uber said an accounting change in the United Kingdom reduced its reported revenue growth, and it forecast current-quarter adjusted profit below Wall Street estimates[4].
- Disney reported fiscal third-quarter revenue of about $25.2 billion versus a consensus estimate of about $25.41 billion, reiterated its full-year outlook, and its shares rose more than 4% in premarket trading[6].
- Novo Nordisk reported second-quarter adjusted sales of 78.49 billion Danish kroner, up 7%, and adjusted operating profit of 33.39 billion kroner, up 11%[9][11].
- Novo Nordisk improved its full-year forecast to adjusted sales and operating profit between down 6% and flat at constant exchange rates, from a prior range of down 4% to down 12%[9].
- The Bureau of Labor Statistics is scheduled to release the July 2026 employment report on Friday, August 7, 2026[17].
- In November 2025, Eli Lilly and Novo Nordisk announced agreements with the Trump administration under which injectable GLP-1 drugs would be priced at $350 a month at launch on TrumpRx, declining to $245 over two years, while new oral versions would start at $149 a month, for Medicare, Medicaid and TrumpRx users[18][22].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Beat the number, not the business
- A quarterly report is scored against a consensus estimate — the average of analyst forecasts. Companies guide those forecasts down where they can, so that the result clears the bar. This is why a company can grow sales 7% and improve its outlook and still see its stock fall 6% in a day[9][11]. It is also why Shopify fell 16% after beating estimates in the first quarter: the beat was smaller than what buyers had already paid for[15].
- Volume versus price in obesity drugs
- Both Lilly and Novo agreed in November 2025 to lower U.S. prices under 'most-favored-nation' deals. Most-favored-nation pricing ties what a company can charge in the U.S. to the lower prices it charges in other wealthy countries; the administration's rationale is that Americans have long paid multiples of what other countries pay for the same drugs, while industry's counter-argument is that higher U.S. prices subsidize the research that produces new drugs used worldwide, so capping U.S. prices to overseas levels risks slowing future drug development. Under the deals, injectable GLP-1 drugs launch on TrumpRx at $350 a month, declining to $245 over two years, while new oral pills start at $149 a month, for Medicare, Medicaid and TrumpRx buyers[18][22]. Lower price per prescription means each company must sell many more prescriptions just to stand still. Lilly's 48% revenue growth came 'primarily by volume,' with prices working against it — that split is the whole ballgame for both firms[2].
- Currency is not performance
- Novo reports in Danish kroner and Uber earns in dozens of currencies. Both used the phrase 'constant exchange rates' or flagged foreign-exchange effects, meaning results with currency swings stripped out[4][9]. A weaker dollar can flatter or depress reported growth without a single extra sale. Uber specifically said currency would trim next quarter's bookings growth[4].
- Spend now, prove it later
- Uber committed more than $10 billion to autonomous vehicles while authorizing a $20 billion buyback[4][5]. Shopify flagged higher AI infrastructure costs[14]. Disney is absorbing rising sports-rights fees[8]. All three are trading current profit for position in a market that does not exist yet at scale. Nobody can verify the payoff from a quarterly report.
- The Fed sets the discount rate on all of it
- Three Federal Reserve regional presidents dissented in favor of an immediate rate hike at the last policy meeting[16]. Higher rates make future profits worth less today, which hits fast-growing companies hardest. That mechanism, not company news, is the most likely explanation for the 20-point gap between growth and value stocks this year[16].
Material realityFive large companies filed audited quarterly numbers, and those numbers are not in dispute. Lilly grew revenue 48% to $23.0 billion and raised its full-year forecast[2]. Novo grew 7% to 78.49 billion kroner and improved a forecast that still describes a down-to-flat year[9]. Uber moved $58.02 billion of gross bookings through its app and kept $14.19 billion as revenue[3][4]. Disney took in about $25.2 billion and held its outlook[6]. Underneath the framing, three physical facts persist. First, demand for GLP-1 obesity and diabetes drugs is still growing faster than either maker can fully supply, and the competitive fight has shifted from injections to pills, which are cheaper to manufacture and distribute[1][10]. Second, U.S. consumers are still buying park tickets, rides, deliveries and online goods at volumes above last year — that shows up in Disney attendance, Uber trips and Shopify merchant sales regardless of how any outlet frames it[3][6][12]. Third, the money these companies earn is being valued against interest rates and a labor market that neither they nor their investors control, and the next hard reading on that arrives Friday, August 7[16][17].
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asLilly's strongest case is that it is not riding a fad but building a category. Revenue grew 48% in one quarter, and the company raised its full-year forecast for the second time this year[2]. Its argument on price is that volume, not price, is doing the work: it agreed to lower U.S. prices under the most-favored-nation deals and still grew[2][18]. Lilly also argues the pipeline matters more than any single quarter. It won FDA approval of Foundayo — the brand name for orforglipron, a weight-loss drug taken as a pill rather than an injection — and has now filed for approval in type 2 diabetes as well[2]. A pill is easier to make and ship at scale than an injector pen, which is why Lilly treats it as the next phase rather than a line item[1].
WhyLilly wants to lock in the obesity market before rivals and before generic pressure arrives, and to keep the political relationship with Washington cooperative so that price rules are negotiated rather than imposed[18].
Impact on themLilly held about 60.1% of the U.S. obesity and diabetes drug market in the first quarter of 2026, against about 39.4% for Novo Nordisk[20]. Options markets going into the report implied a possible swing of roughly $65.9 billion in Lilly's market value on the result — a measure of how much rides on one release[1].
Frames it asNovo's case is that it is being judged against a curve, not against itself. It raised its outlook and still grew sales 7% to 78.49 billion kroner[9][11]. Its leadership argues the new Wegovy pill is priced to win volume and access, not to protect margin — a deliberate trade of price for reach[10]. Novo's deeper argument is about supply and time: it built injectable manufacturing capacity ahead of demand, and it holds long-term cardiovascular outcome data that insurers use to justify coverage. Losing a quarter of share, in that view, is not the same as losing the market.
WhyNovo needs to slow the loss of U.S. share to Lilly and prove that a pill can be sold profitably at low prices, without pulling the price of its injectables down with it[10].
Impact on themShares fell more than 6% after the report despite the improved outlook, which analysts at BMO Capital Markets attributed to the Wegovy pill miss and softer U.S. injectable sales[9][11]. Note what the improved guidance actually says: even at the better end, Novo expects the full year to be flat to down 6% in constant-currency terms — that is, stripping out exchange-rate moves[9].
Frames it asDisney's argument is that its parts reinforce each other. A hit film feeds the parks, and the parks feed the streaming catalog. It points to Toy Story 5 driving studio revenue, higher park attendance, and improved streaming profit, and it reiterated its full-year outlook rather than trimming it[6]. Management's framing is that streaming has crossed from a cash drain into a profit center: the company had targeted an entertainment streaming operating margin of at least 10% for fiscal 2026[8]. On sports, Disney argues that rising rights fees are the price of holding an audience that will not pirate or skip live games.
WhyDisney wants investors to value it as a growing platform company rather than a declining cable company, and to give a new chief executive room to operate[6].
Impact on themThis was the second quarterly report under CEO Josh D'Amaro, who took over less than five months earlier[6]. Revenue of about $25.2 billion fell short of the roughly $25.41 billion consensus, but shares still rose more than 4% premarket — a sign investors weighted profit and guidance over the top-line miss[6].
Frames it asBoth argue the same thing in different markets: spend now to own the next platform shift. Uber's case is that gross bookings — the total dollar value of rides and deliveries flowing through the app, before Uber's cut — grew faster than expected, at $58.02 billion[3][4]. That is the demand signal. Revenue is what Uber keeps, and it came in slightly light partly because of a UK accounting change, which alters how sales are recorded without changing the underlying business[4]. Uber's second argument is that partnering with many robotaxi builders — Rivian, Zoox, Verne and Pony.ai among them — is cheaper and less risky than building self-driving cars itself, while still committing more than $10 billion over coming years[4]. Shopify's parallel case is scale plus AI tooling: merchants on its platform cleared more than $100 billion in gross merchandise volume in the first quarter, the total value of goods sold through its stores, with revenue up 34% to $3.17 billion[12].
WhyBoth want to be judged on growth and market position rather than near-term profit, because both are spending heavily — Uber on autonomous vehicles, Shopify on AI infrastructure[4][14].
Impact on themUber forecast current-quarter adjusted profit below estimates, citing currency effects on bookings growth, and authorized a $20 billion share buyback[4][5]. Shopify shows the risk of high expectations directly: after its first-quarter beat, the stock fell 16%[15]. For the second quarter, analysts expected revenue near $3.43–3.44 billion and earnings per share of roughly $0.37 to $0.40[13][14].
Frames it asThis camp argues that no single company tells you about the economy, and that the batch has to be read together. Its strongest point is that the results split cleanly: drug demand is booming, ride-hailing and delivery volume is up, but the market punished companies whose forward guidance disappointed. That pattern says expectations, not activity, are what is moving prices. A second argument is that policy dominates. Three Federal Reserve regional presidents dissented in favor of an immediate rate hike at the last policy meeting — an unusually large hawkish split[16]. The July jobs report lands Friday, August 7[17]. If the labor market is hotter than expected, rate expectations move, and that can outweigh any earnings beat.
WhyFund managers and strategists want a framework that explains a market where growth and value stocks have split sharply, and they need the next data point to justify current positioning[16].
Impact on themThe divergence is stark: the Russell 1000 Growth index — a basket of faster-growing U.S. companies — was up just 0.32% for the year, while the Russell 1000 Value index was up 20.67%, a gap of more than 20 percentage points[16]. That means an investor holding classic growth stocks has made almost nothing in 2026, while one holding cheaper, slower-growth names has made about a fifth of their money.
Like this article?
The Bias Ledger average rating 4
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Reuters | U.K.-based international wire, institutional/market audience | 2 | 'Uber forecasts weak quarterly profit, doubles down on robotaxi investment plans' — leads with the guidance shortfall and pairs it with capital spending[4]. | Straight wire construction with minimal adjectives. The one framing choice is 'doubles down,' a gambling metaphor that implies risk-taking where Uber would say 'invests.' The revenue miss is explained by the UK accounting change in the same sentence, which is the fair handling. |
| CNBC | U.S. center, business/investor audience | 3 | Frames each report through the stock reaction — 'Novo Nordisk shares slide after guidance disappoints investors' and 'Disney pops' — putting the market's verdict in the headline before the numbers[6][9]. | The subject of the sentence is the share price, not the company or the customer. Readers absorb 'disappoints' as a fact about the business when it is a fact about expectations. CNBC does correct this in the body, noting Novo actually raised guidance[9]. |
| BioSpace | U.S. life-sciences trade publication, funded by pharma industry recruiting and advertising | 3 | 'Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat' — foregrounds the product-level miss and treats the earnings beat as a concession clause[11]. | 'Stumble' is a judgment word about a single product line that came in 3.22 billion kroner against 3.27 billion expected — a gap of about 1.5%. Trade-press framing tends to weight drug-launch narratives above overall financials because that is what its industry readers trade on. |
| Zacks Investment Research | U.S. quantitative research firm; revenue comes from investment research subscriptions | 4 | 'Disney Stock Before Q3 Earnings: Buy Now or Wait for Results?' — poses the story as a trading decision and supplies consensus estimates as the benchmark[8][14]. | Frames the news entirely around whether the stock beats a number Zacks itself compiles. The company's operations appear only as inputs to that forecast. Its 'consensus estimate' is presented as neutral, but different providers published different Lilly estimates — Benzinga cited $8.84 per share, Alphastreet $6.55 — so the bar a company is judged against is itself contested[1][23]. |
| StockTwits | U.S. retail-investor social platform with an editorial desk | 4 | 'NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future' — states the contradiction openly in the headline[9]. | Unusually, the framing names its own paradox rather than hiding it, which helps the reader. The tell is the phrase 'investors worry,' which attributes a single emotion to a market of buyers and sellers — someone was buying at that price. |
| Benzinga | U.S. retail-trader financial media, advertising- and subscription-funded | 6 | 'Eli Lilly Could Swing $65.9 Billion After Earnings' — leads with the size of the possible market-value move rather than any business fact[1]. | The headline number is derived from options pricing, meaning it measures how much traders are betting on volatility, not anything Lilly did. Presenting it as the news maximizes drama for an audience that trades options. The figure is real; the framing treats a probability as an event. |
| The Motley Fool (Opinion) | U.S. retail investing advisory; revenue from paid stock-picking newsletters | 6 | 'Should You Buy Disney Stock Before Aug. 5?' — an explicit advice frame published days before the report[19]. | This is labeled investing commentary, not news, and its business model is selling recommendations. That is a direct incentive to frame every earnings date as an actionable moment. The underlying facts it cites are accurate; the framing is not neutral and does not claim to be. |
References
- Eli Lilly Could Swing $65.9 Billion After Earnings — Benzinga · U.S. retail-trader financial media; ad- and subscription-funded, oriented to options and short-term trading
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress — Eli Lilly and Company · Primary source; company press release issued via PR Newswire, written to favor the company
- Uber Announces Results for Second Quarter 2026 — Uber Technologies · Primary source; company investor-relations release
- Uber forecasts weak quarterly profit, doubles down on robotaxi investment plans — Reuters · U.K.-headquartered international wire service owned by Thomson Reuters; institutional market audience
- Uber Q2 Earnings: Trips Surge, $20 Billion Stock Buyback, CEO Sees No Slowdown — Yahoo Finance · U.S. aggregator; ad-funded, republishes third-party financial media
- Disney (DIS) earnings Q3 2026 — CNBC · U.S. business network owned by Comcast/NBCUniversal; investor-oriented, center on political questions
- The Walt Disney Company Executives to Discuss Fiscal Third Quarter 2026 Financial Results via Webcast — The Walt Disney Company · Primary source; company investor-relations notice
- Disney Stock Before Q3 Earnings: Buy Now or Wait for Results? — Zacks Investment Research · U.S. quantitative research firm selling stock rankings and research subscriptions
- Novo Nordisk shares slide after guidance disappoints investors — CNBC · U.S. business network owned by Comcast/NBCUniversal
- Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall — CNBC · U.S. business network owned by Comcast/NBCUniversal
- Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat — BioSpace · U.S. life-sciences trade publication funded by pharmaceutical-industry recruitment advertising
- Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV — Shopify · Primary source; company press release
- Shopify to Announce Second Quarter 2026 Financial Results — StockTitan · U.S. automated press-release aggregation service for investors
- Pre-Q2 Earnings: Is Shopify Stock a Portfolio Must-Have? — Zacks Investment Research · U.S. quantitative research firm selling stock rankings and research subscriptions
- Shopify Stock Drops 16% After Q1 Beat: Is the Selloff an Overreaction? — TIKR · U.S. investment-data platform; markets its own screening subscription
- Weekly Market Commentary - August 3, 2026 — Clearbrook Global Advisors · U.S. institutional investment advisory firm; commentary written for asset-allocation clients
- Schedule of Selected Releases for August 2026 — U.S. Bureau of Labor Statistics · U.S. federal statistical agency; primary government source
- Trump, Eli Lilly, Novo Nordisk unveil deals to cut obesity drug prices — CNBC · U.S. business network owned by Comcast/NBCUniversal
- Should You Buy Disney Stock Before Aug. 5? — The Motley Fool · U.S. retail investing advisory; revenue from paid stock-recommendation newsletters
- Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader — 24/7 Wall St. · U.S. ad-supported financial commentary site
- Forex Signals August 5: LLY, SNDK, NVO, Disney, Shopify, UBER Earnings Preview — FX Leaders · Israel-based retail forex signal service; monetized through broker referrals
- Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices — The American Journal of Managed Care · U.S. managed-care trade journal; audience is insurers and pharmacy benefit managers
- Eli Lilly and Company (LLY) Q2 2026 Preview: EPS Est. $6.55, Reports August 5 — AlphaStreet · U.S. earnings-data and transcript service for retail investors